Cure Ventures, a life sciences venture capital firm focusing on company formation around curative technologies, has closed its inaugural fund, Cure Ventures Fund I, at its targeted hard-cap of $350 million in capital commitments.Â
Cure Ventures (Cure), a life sciences venture capital firm focusing on company formation around curative technologies, has closed its inaugural fund, Cure Ventures Fund I, at its targeted hard-cap of $350 million in capital commitments.
The fund is supported by a strong syndicate of both US and internationally-based investors that include state and city public pension funds, foundations and endowments, fund-of-funds, hospital and health systems, sovereign wealth funds and family offices.
Cure Ventures is focused on early-stage investments in life science and biotechnology, primarily focused in new therapeutics. Embedded Cure operators will work alongside portfolio company founders to drive day-to-day decision making.
Cure leverages a seed funding model, allowing for important de-risking activities – a critical step in the early drug development process. As part of this process, Cure intends to follow through and co-lead subsequent Series A and B rounds of promising companies.
Cure Ventures was founded by a network of highly accomplished industry veterans, including Managing Partners, Richard (Rich) Lim, MBA; David (Dave) Fallace, JD, MBA; and Lou Tartaglia, PhD. The managing partners have played major roles in the success of several biotechnology companies, including Juno Therapeutics, Agios Therapeutics, Nuvation Bio and many others.
